Bachorik P S, Kwiterovich P O
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.
Clin Chim Acta. 1988 Nov;178(1):1-34. doi: 10.1016/0009-8981(88)90265-3.
Qualitative and quantitative measurements of apolipoproteins such as Apo CII and Apo E, as well as Apo AI and Apo B can aid in the diagnosis of specific lipoprotein metabolic defects. When used in this way, their usefulness will probably remain more or less confined to specialized research centers which have the expertise to perform such analyses and interpret the measurements. In addition, however, Apo AI and Apo B also promise to be useful for the estimation of cardiovascular risk both in individuals and in populations, and both of these apolipoprotein measurements will probably supplement rather than replace conventional lipoprotein measurements. As with the lipoproteins, the usefulness of Apo AI and Apo B measurements will depend on the accuracy and precision with which they can be measured. The current standardization efforts should lead to the development of reference methods for the measurement of total plasma levels of Apo AI and Apo B, the availability of reference materials for these apolipoproteins, and eventually, to the establishment of methods that can specifically measure Apo AI and Apo B in particular lipoprotein subfractions.
对载脂蛋白如载脂蛋白CII和载脂蛋白E以及载脂蛋白AI和载脂蛋白B进行定性和定量测量，有助于诊断特定的脂蛋白代谢缺陷。以这种方式使用时，它们的用途可能或多或少仍局限于具备进行此类分析和解读测量结果专业知识的专业研究中心。然而，此外，载脂蛋白AI和载脂蛋白B在评估个体和人群的心血管风险方面也有望发挥作用，并且这两种载脂蛋白测量可能会补充而非取代传统的脂蛋白测量。与脂蛋白一样，载脂蛋白AI和载脂蛋白B测量的有用性将取决于测量的准确性和精密度。当前的标准化工作应会促成用于测量血浆中载脂蛋白AI和载脂蛋白B总水平的参考方法的开发、这些载脂蛋白参考物质的可得性，并最终促成能够特异性测量特定脂蛋白亚组分中载脂蛋白AI和载脂蛋白B的方法的建立。
